Business, energy, technology, markets and global industry news from Business News Today

rare liver disease

PharmaDeviceNews rare liver disease
Representative image of a hepatology researcher reviewing rare liver disease clinical data, reflecting Mirum Pharmaceuticals’ EASL 2026 updates on volixibat, brelovitug and maralixibat across PSC, HDV and PFIC programs.
Pharma & Biotech

Can volixibat and brelovitug expand Mirum Pharmaceuticals’ rare liver disease ambitions?

Mirum Pharmaceuticals’ EASL 2026 data deepen its rare liver disease strategy. Find out what changes for PSC, HDV and PFIC care.

Read More
Representative image of liver disease drug research and clinical data analysis. Zydus’ FDA Priority Review for saroglitazar highlights the growing treatment competition in primary biliary cholangitis.
Pharma & Biotech

Zydus gains FDA Priority Review for saroglitazar as PBC treatment competition intensifies

Zydus’ saroglitazar gets FDA Priority Review in PBC, setting up a key test for dual PPAR therapy in rare liver disease.

Read More
Representative image: Clinical researchers review liver disease imaging and trial data as Mirum Pharmaceuticals prepares to share VISTAS study results for volixibat in primary sclerosing cholangitis.
Pharma & Biotech

Is volixibat the next major growth lever for Mirum Pharmaceuticals beyond LIVMARLI?

Mirum has commercial momentum. VISTAS will test whether volixibat can extend that rare liver disease story into PSC.

Read More
Pharma & Biotech

What Mirum’s Bluejay acquisition reveals about its long-term liver disease strategy

Mirum adds brelovitug in HDV through Bluejay deal. See how this could redefine rare liver disease leadership ahead of AZURE Phase 3 results in 2026.

Read More